IKS Health Q4 FY26: Margin expansion, cash flow strength, and a platform bet on AI plus EHR

IKS Health ended Q4 FY26 with a familiar pattern for the last few quarters: revenue growth that outpaces operating cost growth, translating into steady margin expansion. Revenue from operations for Q4 FY26 came in at INR 8,577 million, up 18.5% year on year and 5.2% quarter on quarter. EBITDA rose faster at INR 3,002 million, expanding the EBITDA margin to 35.0% versus 31.2% in Q4 FY25. Profit after tax for the quarter was INR 2,060 million, a PAT margin of 24.0%.

For the full year FY26, the company reported INR 31,938 million in revenue from operations, up 19.9% year on year. EBITDA increased 38.0% year on year to INR 10,913 million, taking the margin to 34.2% from 29.7% in FY25. PAT grew 48.4% to INR 7,216 million, implying a PAT margin of 22.6%. Management repeatedly emphasized the operating leverage in the model, pointing to revenue scaling faster than headcount.

The operating model: scaling provider outsourcing with a platform lens

IKS positions itself as a care enablement platform that helps US healthcare providers outsource administrative tasks across the patient journey. The company’s own market framing in the investor presentation puts the total addressable market at USD 260 billion, with an outsourced market of about USD 34 billion and an expected 2023 to 2028E outsourced CAGR of 12%.

Client relationships remain long-tenured and repeat-heavy. The company reported 600 plus healthcare organizations as clients as of Q4 FY26, with 90% plus revenues from repeat customers. Management clarified on the call that the client count has come down from prior years due to deliberate pruning of smaller AQuity-inherited clients, and that it expects to settle in a 500 to 600 client range.

In FY26, the top 10 customers contributed INR 11,811 million, or 37.0% of revenue. The top 5 contributed INR 6,856 million, or 21.5%. Management acknowledged that quarterly mix can swing and advised investors to interpret concentration and growth trends on a full-year basis.

Financial summary

AI agenda and product execution: autonomy, but with human oversight

The investor presentation and concall both spend significant time on the company’s AI strategy. IKS describes an “AI-native, agentic platform” approach across features such as clinical documentation, coding, prior authorization, and patient engagement.

During the quarter, the company highlighted multiple AI-related launches and initiatives.

First, management discussed launching an interconnected agentic workflow for autonomous clinical documentation, coding, and prior authorization. Second, it announced a multi-variant expansion of its ambient scribe product, positioned as a response to real-world physician usage limitations. Management noted that ambient scribing adoption often plateaus at roughly half to two-thirds of patient encounters because certain visits require too much physician editing. The company’s answer is a configurable approach where more complex encounters can use human-in-the-loop support while simpler visits can use a more autonomous mode.

Third, IKS pointed to its AI-driven revenue cycle management and autonomous coding engine. The presentation states that the autonomous coding engine can deliver up to 95% coding accuracy and is integrated with Epic via the Epic Connection Hub, combining AI code assignment with expert human review. The company also launched MyCareHub, described as an agentic AI self-orchestrating platform for patient engagement workflows and also available via Epic Connection Hub.

On the call, management explained a key constraint behind automation potential: tasks with deterministic outcomes require neuro-symbolic approaches, combining generative AI with logic and reasoning frameworks such as knowledge graphs and ontologies. It also highlighted dependence on external ecosystem readiness, for example payer systems and interfaces, which can limit end-to-end autonomy.

Cash generation and balance sheet: deleveraging continues, but a major new lever is proposed

IKS reported strong cash flow generation in FY26. Operating cash flow rose to INR 8,637 million from INR 4,340 million in FY25. Free cash flow increased to INR 6,129 million from INR 2,755 million. Net debt reduced to INR 2,510 million as of March 31, 2026, down from INR 5,627 million at March 31, 2025.

The management team also provided accounting context for quarterly profitability. For Q4 FY26, the CFO said the net currency benefit was about INR 23 crores after considering a hedge loss. Other expenses increased quarter on quarter primarily due to one-time due diligence and legal fees related to the proposed TruBridge acquisition, and management expects additional transaction expenses in Q1 while regulatory approvals remain in progress.

The biggest strategic shift proposed for the next phase is the acquisition of TruBridge.

In its stock exchange disclosure dated April 23, 2026, the company stated that its US subsidiary agreed to acquire 100% of TruBridge for total consideration of up to USD 565 million, subject to customary adjustments. The acquisition is proposed to be funded through facilities up to USD 670 million arranged by global banks. The disclosure also lays out an extensive security package, including pledges of shares and security interests over substantially all assets of certain group entities, along with corporate guarantees including a company guarantee up to 1.05 times of the facilities commitments.

Management’s strategic rationale, as explained on the call and in the presentation, is to combine a system of record with a system of action. TruBridge brings an EHR footprint in rural and community hospitals, and IKS believes linking the EHR with its agentic platform can reduce friction and create compounding value through tighter workflow integration and better access to structured clinical data.

Alongside TruBridge, the company also announced ARAI as a technology-focused addition. The investor presentation states an acquisition price of USD 1.2 million upfront cash for IP, with discounted ESOPs over four years. ARAI is described as bringing knowledge graph IP, clinical ontology, and clinical decision support capabilities, aimed at making AI outputs more transparent and auditable, and reducing hallucination risk.

Takeaways

IKS Health’s FY26 story, as presented in the investor deck and earnings call, is a blend of high-margin scaling and a deliberate shift toward deeper platform integration through agentic AI. The financials show a clear operating leverage trend, supported by strong cash flow conversion and continued net debt reduction.

The next phase, however, is not just about incremental AI features. The proposed TruBridge acquisition is positioned as a structural move toward owning a system of record that can strengthen the data flywheel for AI and create an integrated offering for rural and community hospitals. That strategic upside comes with visible execution requirements, near-term transaction costs, and a significantly larger financing and security framework. Investors will likely watch for progress on approvals, integration cadence, and how the company balances deleveraging with product and platform build-out.